MTOR signaling cascade in psoriatic disease: Double kinase mTOR inhibitor a novel therapeutic target

Indian Journal of Dermatology

Volumn 59, Issue 1, 2014, Pages 67-70

  Raychaudhuri, Smriti K ^a,b   Raychaudhuri, Siba P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Functional significance; mTOR; Psoriasis; Psoriatic arthritis; Therapy

Indexed keywords

DACTOLISIB; GROWTH FACTOR; INTERLEUKIN 17; INTERLEUKIN 22; MAMMALIAN TARGET OF RAPAMYCIN; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR;

ARTICLE; CELL PROLIFERATION; FIBROBLAST; HUMAN; IMMUNE DYSREGULATION; KERATINOCYTE; NEGATIVE FEEDBACK; PATHOGENESIS; POSITIVE FEEDBACK; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; UPREGULATION;

EID: 84891947565     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.123499     Document Type: Article

References (25)

1. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005;69:79-100.
2. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, et al. Insulin activation of rheb, a mediator of mTOR/ S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003;11:1457-66.
3. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006;26:63-76.
4. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 2007;47:443-67.
5. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
6. Higuchi M, Onishi K, Masuyama N, Gotoh Y. The phosphatidylinositol-3 kinase (PI3K)-Akt pathway suppresses neurite branch formation in NGF-treated PC12 cells. Genes Cells 2003;8:657-69.
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
8. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
9. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992;89:9267-71.
10. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009;145:569-80.
11. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009;18:1333-49.
12. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
13. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687-9.
14. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901.
15. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
16. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005;18:89-94.
17. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and - independent pathways. Cancer Cell 2003;4:147-58.
18. Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 2005;280:32856-65.
19. Kim Y, Seger R, Suresh Babu CV, Hwang SY, Yoo YS. A positive role of the PI3-K/Akt signaling pathway in PC12 cell differentiation. Mol Cells 2004;18:353-9.
20. Mitra A, Raychaudhuri SK, Raychaudhuri SP. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 2012;60:38-42.
21. Saxena A, Raychaudhuri SK, Raychaudhuri SP. Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent. Arthritis Rheum 2011;63:1465-6.
22. Datta Mitra A, Raychaudhuri SP, Abria C, Mitra A, Wright R, Ray R, et al. 1-alpha, 25-Dihydroxyvitamin-D3-3-bromoacetate inhibits keratinocyte proliferation involving AKT/mTOR signaling cascades: A novel therapy for psoriasis. J Invest Dermatol 2013;133:1556-64.
23. Raychaudhuri SP, Raychaudhuri SK, Kondala AR, Herzenberg LA, Herzenberg LA. Nerve growth factor: A key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum 2011;63:3243-52.
24. Buerger C, Malisiewicz B, Eiser A, Hardt K, Boehncke WH. Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br J Dermatol 2013;169:156-9.
25. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. Br J Dermatol 2001;145:438-45.